	US 11,911,381 B2
	Optically active azabicyclo ring derivative
Seiji Kamioka, Osaka (JP); Hitoshi Ban, Osaka (JP); Naoaki Shimada, Osaka (JP); Wataru Hirose, Osaka (JP); Akihiko Arakawa, Odawara (JP); Kazuto Yamazaki, Ikoma (JP); and Kenjiro Hira, Osaka (JP)
Assigned to Sumitomo Pharma Co., Ltd., Osaka (JP)
Filed by Sumitomo Pharma Co., Ltd., Osaka (JP)
Filed on May 23, 2022, as Appl. No. 17/750,721.
Application 17/750,721 is a continuation of application No. 16/629,739, granted, now 11,369,605, previously published as PCT/JP2019/033234, filed on Aug. 26, 2019.
Claims priority of application No. 2018-158315 (JP), filed on Aug. 27, 2018.
Prior Publication US 2022/0288072 A1, Sep. 15, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/506 (2006.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01); C07D 519/00 (2006.01)

CPC A61K 31/506 (2013.01) [A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07D 519/00 (2013.01)]

15 Claims

1. 2-[(4-{7-[(1S,3S,4R,6R)-6-(Cyclopropylmethyl)-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-5-fluoro-N,N-di(propan-2-yl)benzamide mono-L(+)-tartrate in crystal form of form I which is characterized by a powder x-ray diffraction pattern having diffraction angle (2θ°) peaks of 5.3°±0.2°, and 13.0°±0.2°.